Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
US Army
Express Scripts
McKinsey
Accenture
Moodys
Queensland Health
Baxter
Cerilliant

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,795,741

« Back to Dashboard

Which drugs does patent 8,795,741 protect, and when does it expire?

Patent 8,795,741 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty patent family members in five countries.
Summary for Patent: 8,795,741
Title:Methods for treating patients who are candidates for inhaled nitric oxide treatment
Abstract: Disclosed are methods of reducing the risk that a medical treatment comprising inhalation of nitric oxide gas will induce an increase in pulmonary capillary wedge pressure in the patient, leading to pulmonary edema.
Inventor(s): Baldassarre; James S. (Doylestown, PA)
Assignee: INO Therapeutics LLC (Hampton, NJ)
Application Number:13/683,417
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,795,741
Patent Claim Types:
see list of patent claims
Use; Process;

Drugs Protected by US Patent 8,795,741

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-002 Dec 23, 1999 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Mallinckrodt Hosp INOMAX nitric oxide GAS;INHALATION 020845-003 Dec 23, 1999 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,795,741

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,431,163 Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas ➤ Sign Up
8,282,966 Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide ➤ Sign Up
8,846,112 Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation ➤ Sign Up
8,293,284 Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Chinese Patent Office
Healthtrust
US Army
Mallinckrodt
Queensland Health
Express Scripts
AstraZeneca
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.